This trial is active, not recruiting.

Conditions eosinophilic granulomatosis with polyangiitis (churg-strauss) (egpa), churg-strauss syndrome (css), granulomatosis with polyangiitis (wegener's) (gpa), wegener granulomatosis (wg), microscopic polyangiitis (mpa), anca-associated vasculitis (aav), vasculitis
Treatment online questionnaire
Sponsor University of Pennsylvania
Collaborator University of Oxford
Start date July 2015
End date December 2016
Trial size 500 participants
Trial identifier NCT02507024, VCRC 5537


The aim of this project is to develop a disease specific patient reported outcome measure (PROM) for patients with AAV (the AAV-PRO). Investigators are developing and validating a questionnaire to assess quality of life in patients with ANCA-associated vasculitis (AAV). Patients with AAV have inflammation in the small blood vessels leading to involvement of a range of organs and can suffer from ongoing disease activity or treatment side effects. Quality of life can be measured by patient reported outcome measures (PROMs).

United States No locations recruiting
Other countries No locations recruiting

Study Design

Time perspective prospective
The online questionnaire includes questions about how ANCA-associated vasculitis effects patients quality of life.
online questionnaire

Primary Outcomes

Completion of AAV-PRO questionnaire.
time frame: 6 months

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Registered in the Vasculitis Patient-Powered Research Network (V-PPRN) - Patients greater than 18 years of age - Diagnosis of ANCA-associated vasculitis including: Eosinophilic Granulomatosis with Polyangiitis (also called Churg-Strauss Syndrome), Granulomatosis with Polyangiitis (also called Wegener's granulomatosis or GPA), Microscopic Polyangiitis (MPA)

Additional Information

Official title The ANCA Vasculitis Questionnaire (AAV-PRO©)
Principal investigator Joanna Robson, MD
Description Patients with ANCA-associated vasculitis have inflammation in the small vessels that impact a range of organs and Investigators understand that patients may suffer ongoing disease activity, as well as side effects from the treatments. Assessing patients quality of life can be an important tool for conducting clinical trials for new treatments and medications. Quality of life can be measured by questionnaires called "patient reported outcome measures" (PROM). What is a patient-reported outcome? Patient-reported outcomes, or PROs, are patients' feedback on what they are feeling or what they are able to do as participants are dealing with a chronic disease . Patient-reported outcomes are important because they provide doctors and researchers information about patients' quality of life. Questionnaires can be designed to measure specific PROs that are of specific importance to a disease and can provide much needed information on evaluating the effectiveness of health care. The aim of this survey is to develop a disease specific patient reported outcome measure, or PROM, for patients with AAV. A small group of Investigators and Patient-Partners developed this survey for people with ANCA-associated vasculitis (the AAV-PRO). Investigators will invite patients with AAV to complete the questionnaire they have designed, called the AAV-PRO. By analysing how people fill in the questionnaire, Investigators will be able to find out how well the questions work, and whether they need to ask all of them.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by University of Pennsylvania.